Cite
HARVARD Citation
Meric-Bernstam, F. et al. (n.d.). O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Annals of oncology. p. . [Online].